Skip to main content
NCBI home page
Gut logoLink to Gut
. 1998 Aug;43(2):182–186. doi: 10.1136/gut.43.2.182

Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases

D Basso 1, F Navaglia 1, L Brigato 1, M Piva 1, A Toma 1, E Greco 1, M Di 1, F Galeotti 1, G Roveroni 1, A Corsini 1, M Plebani 1
PMCID: PMC1727228  PMID: 10189841

Abstract

Background—Helicobacter pylori species comprise different strains, cytotoxic and non-cytotoxic, which can be identified on the basis of their genomic pattern.
Aims—(1) To evaluate the polymorphism of the vacA gene and to ascertain whether the cagA gene is present in patients with gastric adenocarcinoma. (2) To study the anti-H pylori antibody profile using western blotting. 
Patients—Twenty one patients with gastric adenocarcinoma and 71 with H pylori associated benign disease (nine gastric ulcer, 29 duodenal ulcer, 25 antral gastritis, and eight duodenitis). 
Methods—The polymerase chain reaction was used to verify the presence or absence of cagA and to study the polymorphism of vacA in gastric mucosal samples obtained during endoscopy for patients with benign diseases and at surgery for patients with gastric adenocarcinoma. Fasting sera were used to assess anti-H pylori antibodies against different H pylori antigens by western blotting. 
Results—cagA gene and the allele s1 of vacA were significantly less frequent in patients with antral gastritis (60% and 60%) compared with patients with gastric adenocarcinoma (94% and 100%) and with other non-malignant gastroduodenal diseases (93% and 87%) (χ2=16.01, p<0.001; and χ2=13.97, p<0.01). In patients with gastric adenocarcinoma, antibodies against a 74 kDa H pylori antigen were less frequently found than in patients with benign diseases. 
Conclusions—H pylori infection caused by cagA positive/vacA s1 strains is a frequent finding in patients with gastric adenocarcinoma. Prospective studies are needed to confirm whether the low incidence of positive serological response to the 74 kDa H pylori antigen in patients with gastric adenocarcinoma is important. 



Keywords: Helicobacter pylori; western blot; cagA; vacA; gastric adenocarcinoma

Full Text

The Full Text of this article is available as a PDF (127.8 KB).

Figure 1 .

Figure 1

Open in a new tab

Individual values of anti-H pylori antibodies. 


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asaka M., Kimura T., Kato M., Kudo M., Miki K., Ogoshi K., Kato T., Tatsuta M., Graham D. Y. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer. 1994 Jun 1;73(11):2691–2694. doi: 10.1002/1097-0142(19940601)73:11<2691::aid-cncr2820731107>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  2. Atherton J. C., Cao P., Peek R. M., Jr, Tummuru M. K., Blaser M. J., Cover T. L. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995 Jul 28;270(30):17771–17777. doi: 10.1074/jbc.270.30.17771. [DOI] [PubMed] [Google Scholar]
  3. Atherton J. C., Peek R. M., Jr, Tham K. T., Cover T. L., Blaser M. J. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 1997 Jan;112(1):92–99. doi: 10.1016/s0016-5085(97)70223-3. [DOI] [PubMed] [Google Scholar]
  4. Baik S. C., Youn H. S., Chung M. H., Lee W. K., Cho M. J., Ko G. H., Park C. K., Kasai H., Rhee K. H. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res. 1996 Mar 15;56(6):1279–1282. [PubMed] [Google Scholar]
  5. Banerjee S., Hawksby C., Miller S., Dahill S., Beattie A. D., McColl K. E. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. Gut. 1994 Mar;35(3):317–322. doi: 10.1136/gut.35.3.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Basso D., Navaglia F., Cassaro M., Scrigner M., Toma A., Dal Bo N., Di Mario F., Rugge M., Plebani M. Gastric juice polymerase chain reaction: an alternative to histology in the diagnosis of Helicobacter pylori infection. Helicobacter. 1996 Sep;1(3):159–164. doi: 10.1111/j.1523-5378.1996.tb00031.x. [DOI] [PubMed] [Google Scholar]
  7. Bayerdörffer E., Neubauer A., Rudolph B., Thiede C., Lehn N., Eidt S., Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995 Jun 24;345(8965):1591–1594. doi: 10.1016/s0140-6736(95)90113-2. [DOI] [PubMed] [Google Scholar]
  8. Blaser M. J., Chyou P. H., Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 1995 Feb 1;55(3):562–565. [PubMed] [Google Scholar]
  9. Blaser M. J., Perez-Perez G. I., Kleanthous H., Cover T. L., Peek R. M., Chyou P. H., Stemmermann G. N., Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995 May 15;55(10):2111–2115. [PubMed] [Google Scholar]
  10. Brenes F., Ruiz B., Correa P., Hunter F., Rhamakrishnan T., Fontham E., Shi T. Y. Helicobacter pylori causes hyperproliferation of the gastric epithelium: pre- and post-eradication indices of proliferating cell nuclear antigen. Am J Gastroenterol. 1993 Nov;88(11):1870–1875. [PubMed] [Google Scholar]
  11. Cover T. L., Glupczynski Y., Lage A. P., Burette A., Tummuru M. K., Perez-Perez G. I., Blaser M. J. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol. 1995 Jun;33(6):1496–1500. doi: 10.1128/jcm.33.6.1496-1500.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cover T. L. The vacuolating cytotoxin of Helicobacter pylori. Mol Microbiol. 1996 Apr;20(2):241–246. doi: 10.1111/j.1365-2958.1996.tb02612.x. [DOI] [PubMed] [Google Scholar]
  13. Craanen M. E., Blok P., Dekker W., Tytgat G. N. Helicobacter pylori and early gastric cancer. Gut. 1994 Oct;35(10):1372–1374. doi: 10.1136/gut.35.10.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Crabtree J. E., Wyatt J. I., Sobala G. M., Miller G., Tompkins D. S., Primrose J. N., Morgan A. G. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut. 1993 Oct;34(10):1339–1343. doi: 10.1136/gut.34.10.1339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Davies G. R., Simmonds N. J., Stevens T. R., Sheaff M. T., Banatvala N., Laurenson I. F., Blake D. R., Rampton D. S. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut. 1994 Feb;35(2):179–185. doi: 10.1136/gut.35.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fontham E. T., Ruiz B., Perez A., Hunter F., Correa P. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol. 1995 Jul;90(7):1094–1101. [PubMed] [Google Scholar]
  17. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol Suppl. 1996;220:23–26. [PubMed] [Google Scholar]
  18. Hansson L. E., Engstrand L., Nyrén O., Evans D. J., Jr, Lindgren A., Bergström R., Andersson B., Athlin L., Bendtsen O., Tracz P. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology. 1993 Oct;105(4):1098–1103. doi: 10.1016/0016-5085(93)90954-b. [DOI] [PubMed] [Google Scholar]
  19. Hirai M., Azuma T., Ito S., Kato T., Kohli Y., Fujiki N. High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric-carcinoma patients. Int J Cancer. 1994 Jan 2;56(1):56–60. doi: 10.1002/ijc.2910560111. [DOI] [PubMed] [Google Scholar]
  20. Hwang H., Dwyer J., Russell R. M. Diet, Helicobacter pylori infection, food preservation and gastric cancer risk: are there new roles for preventative factors? Nutr Rev. 1994 Mar;52(3):75–83. doi: 10.1111/j.1753-4887.1994.tb01394.x. [DOI] [PubMed] [Google Scholar]
  21. Klaamas K., Held M., Wadström T., Lipping A., Kurtenkov O. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Int J Cancer. 1996 Jul 3;67(1):1–5. doi: 10.1002/(SICI)1097-0215(19960703)67:1<1::AID-IJC1>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  22. Kuipers E. J., Meuwissen S. G. Helicobacter pylori and gastric carcinogenesis. Scand J Gastroenterol Suppl. 1996;218:103–105. [PubMed] [Google Scholar]
  23. Labenz J., Börsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994 Jan;35(1):19–22. doi: 10.1136/gut.35.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mitchell H. M., Hazell S. L., Li Y. Y., Hu P. J. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol. 1996 Sep;91(9):1785–1788. [PubMed] [Google Scholar]
  25. Murakami K., Fujioka T., Kodama R., Kubota T., Tokieda M., Nasu M. Helicobacter pylori infection accelerates human gastric mucosal cell proliferation. J Gastroenterol. 1997 Apr;32(2):184–188. doi: 10.1007/BF02936365. [DOI] [PubMed] [Google Scholar]
  26. Navaglia F., Basso D., Piva M. G., Brigato L., Stefani A., Dal Bò N., Di Mario F., Rugge M., Plebani M. Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology. Am J Gastroenterol. 1998 Feb;93(2):227–230. doi: 10.1111/j.1572-0241.1998.00227.x. [DOI] [PubMed] [Google Scholar]
  27. Parsonnet J., Friedman G. D., Orentreich N., Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997 Mar;40(3):297–301. doi: 10.1136/gut.40.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Peek R. M., Jr, Miller G. G., Tham K. T., Perez-Perez G. I., Zhao X., Atherton J. C., Blaser M. J. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 1995 Dec;73(6):760–770. [PubMed] [Google Scholar]
  29. Plebani M., Basso D., Cassaro M., Brigato L., Scrigner M., Toma A., Di Mario F., Rugge M. Helicobacter pylori serology in patients with chronic gastritis. Am J Gastroenterol. 1996 May;91(5):954–958. [PubMed] [Google Scholar]
  30. Shibata T., Imoto I., Gabazza E. C. Detection of Helicobacter pylori in biopsy of patients with gastric carcinoma. Biomed Pharmacother. 1997;51(1):22–28. doi: 10.1016/s0753-3322(97)87075-8. [DOI] [PubMed] [Google Scholar]
  31. Shibata T., Imoto I., Ohuchi Y., Taguchi Y., Takaji S., Ikemura N., Nakao K., Shima T. Helicobacter pylori infection in patients with gastric carcinoma in biopsy and surgical resection specimens. Cancer. 1996 Mar 15;77(6):1044–1049. [PubMed] [Google Scholar]
  32. Vollmers H. P., Dämmrich J., Ribbert H., Grassel S., Debus S., Heesemannn J., Müller-Hermelink H. K. Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer. 1994 Sep 1;74(5):1525–1532. doi: 10.1002/1097-0142(19940901)74:5<1525::aid-cncr2820740506>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  33. Wigler P. W. Reversal of multidrug resistance in cancer cells. J Natl Cancer Inst. 1994 Jan 19;86(2):148–150. doi: 10.1093/jnci/86.2.148. [DOI] [PubMed] [Google Scholar]
  34. Yamaoka Y., Kita M., Kodama T., Sawai N., Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology. 1996 Jun;110(6):1744–1752. doi: 10.1053/gast.1996.v110.pm8964399. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES